Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.

Hiroaki IkesueKohei DoiMayu MorimotoMasaki HirabatakeNobuyuki MuroiShinsuke YamamotoToshihiko TakenobuTohru Hashida

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

The results of this study suggest that denosumab poses a significant risk for developing MRONJ in patients treated for bone metastasis, and thus these patients require close monitoring.

Keyphrases

bone mineral density
end stage renal disease
ejection fraction
chronic kidney disease
healthcare
peritoneal dialysis
postmenopausal women
giant cell
prognostic factors
body composition
emergency department
soft tissue
patient reported